bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim

September 22, 2016 7:46 AM EDT
Get Alerts BLUE Hot Sheet
Price: $72.40 +3.80%

Rating Summary:
    15 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade BLUE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of bluebird bio (NASDAQ: BLUE) after Mast Therapeutics' (NASDAQ: MSTX) phase III study (EPIC) of vepoloxamer failed to show efficacy over the placebo.

The analyst considered the problem of what could be done to treat the pain and determined that a cure (via gene therapy) may be the best method. Gene therapy with bluebird's LentiGlobin in just two patients has suggested that targeting the "source" of disease could potentially represent a "cure." The question now is how many patients represent proof of concept (POC), and would the sickle cell community adopt gene therapy? Answering the question will take more patients and more time but the analyst is expecting data from multiple patients at ASH in December.

No change to the price target of $85.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $73.81 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Maxim Group

Add Your Comment